ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M-$1B in U.S. with expanded clinical milestones
Source: SeekingAlpha
2025-11-10 11:23:46 ET
More on ADC Therapeutics
- ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
- ADC Therapeutics SA 2025 Q3 - Results - Earnings Call Presentation
- ADC Therapeutics SA 2025 Q2 - Results - Earnings Call Presentation
- ADC Therapeutics Q3 Earnings Preview
- ADC Therapeutics rises on $60M PIPE financing
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics SA
NASDAQ: ADCT
ADCT Trading
-5.62% G/L:
$4.20 Last:
295,591 Volume:
$4.36 Open:
ADCT Latest News
March 10, 2026 07:30:00 am
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADCT Stock Data
$486,217,661
104,923,913
12.45%
40
N/A
Biotechnology & Life Sciences
Healthcare
CH
Epalinges
